hereditary amyloidosis

Trials

20 participants · First posted Oct 8, 2025

Recruiting

NCT05929209

Exploring Biomarkers in Hereditary Transthyretin Amyloidosis

80 participants · First posted Jul 3, 2023

Enrolling By Invitation

NCT07124377

Phenotypic Manifestations of Hereditary ATTR Amyloidosis

57 participants · First posted Aug 15, 2025

Drugs

View all 41 →

Biotech

Approved

Inotersen(Tegsedi)

Conditions: Hereditary Transthyretin Amyloidosis, Polyneuropathies caused by Hereditary transthyretin-mediated amyloidosis

Rx

amyloidosis therapy, orphanbiotec

Biotech

Approved

Patisiran(Onpattro)

Conditions: Hereditary transthyretin-mediated amyloidosis

Rx

Organizations

View all 4 →

Biora Therapeutics

United States

Astria Therapeutics Inc

United States

Pharming Group

Netherlands

News

View all 501 →

last year

EU Approves WAINZUA (Eplontersen) for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

last year

Swissmedic Authorizes Tegsedi for Hereditary Transthyretin Amyloidosis

last year

Trials

Comprehensive Program for Hereditary Transthyretin Amyloidosis

Exploring Biomarkers in Hereditary Transthyretin Amyloidosis

Phenotypic Manifestations of Hereditary ATTR Amyloidosis

Drugs

Inotersen(Tegsedi)

amyloidosis therapy, orphanbiotec

Patisiran(Onpattro)

Organizations

Biora Therapeutics

Astria Therapeutics Inc

Pharming Group

News

EU Approves WAINZUA (Eplontersen) for Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Swissmedic Authorizes Tegsedi for Hereditary Transthyretin Amyloidosis

Eplontersen (Wainzua) Recommended in England and Wales for Hereditary Transthyretin Amyloidosis